Astria Therapeutics, Inc.
DelistedCIK 1454789fmd_027TNKK09X5MBHBR9EHWSVT1Z9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2025, 48 periods
Latest annual · FY2020
Millions- Total revenues
- 0
- Operating income
- (112)
- Net income
- (94)
- Free cash flow
- (82)
Latest quarter · Q3 FY2025
Millions- Total revenues
- 1
- Operating income
- (34)
- Net income
- (32)
- Free cash flow
- (32)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2019 to FY2024
- n/m
Astria Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Operating income | -$111.6 million | -$83 million | 10-K 2025-03-11 · proof | |
| Net income | -$94.3 million | -$72.9 million | 10-K 2025-03-11 · proof | |
| Cash from operating activities | -$81.2 million | -$68.4 million | 10-K 2025-03-11 · proof | |
| Free cash flow | -$81.5 million | -$68.5 million | 10-K 2025-03-11 · proof | |
| Total assets | $342.4 million | $254.7 million | +34.4% | 10-K 2025-03-11 · proof |
| Total liabilities | $23.1 million | $11.6 million | +100% | 10-K 2025-03-11 · proof |
| Cash and cash equivalents | $59.8 million | $175.5 million | -65.9% | 10-K 2025-03-11 · proof |
- What was Astria Therapeutics, Inc.'s operating income in fiscal 2024?
- Astria Therapeutics, Inc. reported operating income of -$111.6 million for fiscal 2024 (the year ended Dec 31, 2024), against -$83 million the year before. Source: the 10-K filed with the SEC on Mar 11, 2025. SEC
- What was Astria Therapeutics, Inc.'s net income in fiscal 2024?
- Astria Therapeutics, Inc. reported net income of -$94.3 million for fiscal 2024 (the year ended Dec 31, 2024), against -$72.9 million the year before. Source: the 10-K filed with the SEC on Mar 11, 2025. SEC
- What was Astria Therapeutics, Inc.'s cash from operating activities in fiscal 2024?
- Astria Therapeutics, Inc. reported cash from operating activities of -$81.2 million for fiscal 2024 (the year ended Dec 31, 2024), against -$68.4 million the year before. Source: the 10-K filed with the SEC on Mar 11, 2025. SEC
- What was Astria Therapeutics, Inc.'s free cash flow in fiscal 2024?
- Astria Therapeutics, Inc. reported free cash flow of -$81.5 million for fiscal 2024 (the year ended Dec 31, 2024), against -$68.5 million the year before. Source: the 10-K filed with the SEC on Mar 11, 2025. SEC
- What are Astria Therapeutics, Inc.'s total assets?
- As of Dec 31, 2024, Astria Therapeutics, Inc. reported total assets of $342.4 million, against $254.7 million a year earlier (+34.4%). Source: the 10-K filed with the SEC on Mar 11, 2025. SEC
- What are Astria Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2024, Astria Therapeutics, Inc. reported total liabilities of $23.1 million, against $11.6 million a year earlier (+100%). Source: the 10-K filed with the SEC on Mar 11, 2025. SEC
- What are Astria Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2024, Astria Therapeutics, Inc. reported cash and cash equivalents of $59.8 million, against $175.5 million a year earlier (-65.9%). Source: the 10-K filed with the SEC on Mar 11, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1454789&period_type=annual&limit=5"Information only, not investment advice.